{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:59:50Z","timestamp":1781135990822,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Most women face multiple and co-occurring risks from unwanted pregnancy, human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs) at some point during their lifetime. While a range of contraceptive methods exist and options for HIV prevention are increasing, to date, only male and female condoms provide multipurpose protection from both pregnancy and disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From September 2017 to December 2018, 60 women from the United States and the Dominican Republic, randomized 1:1 to continuous or interrupted use and 4:1 to active vs. placebo ring, participated in a Phase I trial to assess the safety and tolerability of a three-month multipurpose intravaginal ring (IVR) containing the antiviral tenofovir and the contraceptive levonorgestrel. This study examines survey responses from all participants and qualitative data from a subset of 17 women to assess acceptability of and preferences for IVR characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, women liked the concept of a multipurpose IVR and found it easy to insert and remove. Initial concerns about the size or thickness of the ring generally disappeared with use experience. Women weighed trade-offs between the ease of continuous use for a longer duration against concerns about hygiene and discoloration of the ring when left in place during menses. Whether randomized to continuous or interrupted use, most women found ring attributes (size, thickness, flexibility) very acceptable. They provided recommendations <jats:italic>via<\/jats:italic> survey and qualitative interviews for ring modifications that would further increase acceptability. Insights into women's use experiences also suggest the need for clear counseling messages and introduction strategies that can facilitate women's choice and use of prevention methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Study findings suggest that a multipurpose IVR would make a valuable contribution to women's sexual and reproductive health options, and that both continuous and interrupted use strategies may be preferred.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frph.2023.1148134","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:34:10Z","timestamp":1680154450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Preferred product attributes of a multipurpose vaginal ring: Findings from a phase 1 trial"],"prefix":"10.3389","volume":"5","author":[{"given":"Elizabeth E.","family":"Tolley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homaira","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Brache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo F.","family":"Doncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1471-0528.12842","article-title":"The need for multipurpose prevention technologies in sub-saharan Africa","volume":"121","author":"Karim","year":"2014","journal-title":"BJOG"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1152","DOI":"10.1016\/S2214-109X(20)30315-6","article-title":"Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990\u20132019","volume":"8","author":"Bearak","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B3","volume-title":"State of world population 2022: Seeing the unseen","year":"2022"},{"key":"B4","volume-title":"UNAIDS Data 2019","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/0272684X16685254","article-title":"Factors influencing contraceptive use in sub-saharan Africa: a systematic review","volume":"37","author":"Blackstone","year":"2017","journal-title":"Int Q Community Health Educ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S222","DOI":"10.1097\/QAI.0000000000002215","article-title":"Insights for implementation science from 2 multiphased studies with end-users of potential multipurpose prevention technology and HIV prevention products","volume":"82","author":"Minnis","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/1471-0528.12851","article-title":"Making the case for multipurpose prevention technologies: the socio-epidemiological rationale","volume":"121","author":"Boonstra","year":"2014","journal-title":"BJOG"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.antiviral.2013.09.019","article-title":"Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel","volume":"100","author":"Brady","year":"2013","journal-title":"Antiviral Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/1471-0528.12844","article-title":"Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies","volume":"121","author":"Brady","year":"2014","journal-title":"BJOG"},{"key":"B10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/IJWH.S34030","article-title":"Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies","volume":"5","author":"Thurman","year":"2013","journal-title":"Int J Womens Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0199778","DOI":"10.1371\/journal.pone.0199778","article-title":"Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women","volume":"13","author":"Thurman","year":"2018","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0275794","DOI":"10.1371\/journal.pone.0275794","article-title":"Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: the CONRAD 138 study","volume":"17","author":"Thurman","year":"2022","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2021.0394","article-title":"Acceptability of a long-acting, multipurpose vaginal ring: findings from a phase I trial in the U.S. and dominican republic","author":"Tolley","year":"2022","journal-title":"J Womens Health (Larchmt)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1071\/SH15045","article-title":"Exploring vaginal ring acceptability for contraception and sexually transmissible infection protection in India: a qualitative research study","volume":"12","author":"Das","year":"2015","journal-title":"Sex Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145642","article-title":"The promise of intravaginal rings for prevention: user perceptions of biomechanical properties and implications for prevention product development","author":"Guthrie","year":"2015","journal-title":"PLoS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0197269","DOI":"10.1371\/journal.pone.0197269","article-title":"User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: a mixed methods study of acceptability and use experiences","volume":"13","author":"Guthrie","year":"2018","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0197572","DOI":"10.1371\/journal.pone.0197572","article-title":"A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: safety of intermittent and continuous use","volume":"13","author":"Kestelyn","year":"2018","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20224898","DOI":"10.1016\/j.contraception.2021.10.001","article-title":"Vaginal ring acceptablity and related preferences among women in low- and middle-income countries: a systematic review and narrative synthesis","volume":"14","author":"Griffin","year":"2019","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.antiviral.2013.09.029","article-title":"Designing a multipurpose technology for acceptability and adherence","volume":"100","author":"Tolley","year":"2013","journal-title":"Antiviral Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2105\/AJPH.2004.043471","article-title":"Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities","volume":"96","author":"Tolley","year":"2006","journal-title":"Am J Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41591-021-01648-4","article-title":"The value of patient-reported outcomes in early-phase clinical trials","volume":"28","author":"Retzer","year":"2022","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2021.10.001","article-title":"Vaginal ring acceptability: a systematic review and meta-analysis of vaginal ring experiences from around the world","volume":"106","author":"Ridgeway","year":"2022","journal-title":"Contraception"},{"key":"B23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/sifp.12209","article-title":"Barriers and enablers influencing Women's adoption and continuation of vaginally inserted contraceptive methods: a literature review","volume":"53","author":"Harris","year":"2022","journal-title":"Stud Fam Plann"},{"key":"B24","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/13691058.2010.507876","article-title":"Intravaginal insertion in KwaZulu-Natal: sexual practices and preferences in the context of microbicide gel use","volume":"12","author":"Gafos","year":"2010","journal-title":"Cult Health Sex"},{"key":"B25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10461-013-0676-9","article-title":"The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa","volume":"18","author":"Gafos","year":"2014","journal-title":"AIDS Behav"},{"key":"B26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.socscimed.2013.12.005","article-title":"Understanding motives for intravaginal practices amongst Tanzanian and Ugandan women at high risk of HIV infection: the embodiment of social and cultural norms and well-being","volume":"102","author":"Lees","year":"2014","journal-title":"Soc Sci Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s10461-019-02457-0","article-title":"A mixed-methods study examining adherence to and acceptability of intravaginal rings for HIV prevention: behavioral results of MTN-027","volume":"24","author":"Bauermeister","year":"2020","journal-title":"AIDS Behav"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","article-title":"Acceptability and use of a dapivirine vaginal ring in a phase III trial","volume":"31","author":"Montgomery","year":"2017","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0147743","DOI":"10.1371\/journal.pone.0147743","article-title":"Safety, acceptability and adherence of dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in sub-saharan Africa","volume":"11","author":"Nel","year":"2016","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1089\/jwh.2021.0121","article-title":"Acceptability and preference for 3-month versus 1-month vaginal rings for HIV-1 risk reduction among participants in a phase 1 trial","volume":"31","author":"Roberts","year":"2022","journal-title":"J Womens Health (Larchmt)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0191251","DOI":"10.1371\/journal.pone.0191251","article-title":"Contexts of vulnerability and the acceptability of new biomedical HIV prevention technologies among key populations in South Africa: a qualitative study","volume":"13","author":"Atujuna","year":"2018","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0178324","DOI":"10.1371\/journal.pone.0178324","article-title":"Association of vaginal dysbiosis and biofilm with contraceptive vaginal ring biomass in African women","volume":"12","author":"Hardy","year":"2017","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0201003","DOI":"10.1371\/journal.pone.0201003","article-title":"Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: a randomised, open-label longitudinal study in Rwandan women","volume":"13","author":"Crucitti","year":"2018","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"12040","DOI":"10.1038\/s41598-022-13475-9","article-title":"Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya","volume":"12","author":"Dabee","year":"2022","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"799501","DOI":"10.3389\/fcimb.2022.799501","article-title":"Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using a 90-day tenofovir\/levonorgestrel vaginal ring","volume":"12","author":"Thurman","year":"2022","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2023.1148134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:34:14Z","timestamp":1680154454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2023.1148134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":35,"alternative-id":["10.3389\/frph.2023.1148134"],"URL":"https:\/\/doi.org\/10.3389\/frph.2023.1148134","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1148134"}}